Ragosa Mark's Form 4 filing
Kiniksa Pharmaceuticals International, plc (KNSA) · filed Sep 3, 2026
- Accession no.
- 0001835458-26-000012
- Filed
- Sep 3, 2026, 4:49 PM ET
- Trade date
- Sep 1, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 6 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ragosa MarkCIK 0001835458 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +2,694 | –F1 | – | 18,848 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +1,750 | –F1 | – | 20,598 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +1,591 | –F1 | – | 22,189 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +3,069 | –F1 | – | 25,258 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | FTax withholdingDisposed | −4,404 | $79.28 | −$349,149.12 | 20,854 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Class A Ordinary Share | AGrant or awardAcquired | +7,800 | $0.00 | $0 | 7,800 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | AGrant or awardAcquired | +31,150 | $0.00 | $0 | 31,150 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −3,069 | $0.00 | $0 | 9,206 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −1,591 | $0.00 | $0 | 3,182 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −1,750 | $0.00 | $0 | 1,750 | Direct | |
| Sep 1, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −2,694 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
Referenced by the price of 4 transactions in Table I.